Small-Cap Biotechnology Stock Jumps 13% As Company Launches €11 Million DENSTAR Project; FII & DII Stakes Increases

On Tuesday, Indian equity benchmarks traded higher, with the benchmark Nifty 50 index rising 0.11 per cent to 23,149.10. Defying the broader market trend, Panacea Biotec's share price jumped 13.76 per cent to Rs 629.00 after the company announced the launch of the DENSTAR project, an international initiative aimed at advancing the licensure and global deployment of its dengue vaccine candidate.

Panacea Biotec Launches DENSTAR Project

Panacea Biotec announced the launch of DENSTAR, a four-year international project focused on supporting the licensure of its tetravalent live-attenuated dengue vaccine candidate, DengiA/1, in sub-Saharan Africa and facilitating broader global adoption.

The project commenced on June 1, 2026, and is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU), supported by the European Union.

The EDCTP contribution to the project amounts to EUR 11.09 million under Grant Number 101249135, with the programme scheduled to run for 48 months.

Panacea Biotec Focuses on Dengue Prevention

DENSTAR aligns with the EDCTP3 mission to address neglected tropical diseases, including dengue fever, which continues to emerge as a growing global public health challenge.

The initiative aims to advance a live-attenuated tetravalent dengue vaccine through immunobridging studies and controlled human infection model studies to support regulatory approval in sub-Saharan Africa, where dengue infections have become increasingly common.

The programme will include Phase I/III clinical studies in healthy African adults and children to evaluate safety and efficacy, alongside assessments of protection against Dengue Virus Serotype 4 (DENV-4).

International Consortium Across Nine Countries

The DENSTAR consortium is coordinated by Sclavo Vaccines Association ETS, Italy, and brings together 10 partners across nine countries spanning Europe, Africa, the United States, India and South Korea.

As the developer of DengiA/1, which is currently in late-stage development in India, Panacea Biotec is a key consortium partner.

According to the company, the vaccine is designed as a single-dose candidate that can be manufactured cost-effectively, scaled for mass deployment and distributed without requiring prior serological testing.

Management Commentary

Dr Khalid Ali Syed, Chief Scientific Officer of Panacea Biotec Limited, said, “The project efforts are expected to have a lasting impact on global health, extending beyond the project's immediate scope and duration by reducing the dengue burden, improving quality of life, alleviating pressure on health systems, and upholding the universal right to a healthy, productive life.”

Also Read - Navratna PSU To Sell Up To 3% Stake Through OFS; Government To Raise Upto Rs 1,263 Crore

Capacity Building And Research Development

The consortium also plans to support public health capacity building through training opportunities for MPH and PhD students and by strengthening the readiness of African clinical trial sites. The initiative aims to create sustainable, locally led research capabilities while advancing vaccine development and regulatory preparedness across participating regions.

About Panacea Biotec

Panacea Biotec Ltd is an India-based biotechnology company engaged in the development, manufacture and marketing of vaccines, biopharmaceuticals and pharmaceutical products. FII holding in Panacea Biotec increased to 1.60 per cent in Q4 FY26 from 1.36 per cent in Q3 FY26, while DII ownership rose to 1.96 per cent from 1.85 per cent during the same period.

The company is the developer of DengiA/1, a tetravalent live-attenuated dengue vaccine candidate currently in late-stage development, and operates across domestic and international healthcare markets.

What are your thoughts on Panacea Biotec's participation in the DENSTAR dengue vaccine project? Share your views in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.